Publications
2 shownDurable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
In patients with advanced IDH1-mutated relapsed or refractory AML, ivosidenib at a dose of 500 mg daily was associated with a low frequency of grade 3 or higher treatment-relate...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 1,787
- Institution
- Agios Pharmaceuticals (United States)
External Links
Identifiers
- ORCID
- 0000-0003-2054-9108
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.